Roche Venture Fund has reinvested in Horizon Discovery's third round of funding.

UK-based personal medicine company Horizon Discovery has raised £6.25m ($9.9m) in its series C round and revealed Switzerland-based pharmaceuticals company Roche as its corporate venturing investor.

Roche Venture Fund has reinvested in Horizon’s third round of funding, which was led by venture capital firm DFJ Esprit as a new investor and included angel investors David Evans, chairman of AIM-quoted Immunodiagnostic Systems, and Jonathan Milner, chief executive of antibody supplier Abcam that has had one of Europe’s most successful flotations in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?